Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UltIMMa-2: BI 655066 versus ustekinumab and placebo in moderate to severe plaque psoriasis
2015-003622-13Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in psoriasis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: PASI 90 response at Week 16. Started Jan 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2015-003622-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003622-13.